The Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 billion.
Sebi to revamp short-selling, securities lending rules
Sebi is reviewing short-selling and securities lending rules to improve liquidity and price discovery. The regulator is also planning reforms in clearing, broker compliance, custodial
October 25, 2026